Why Revvity (RVTY) Is Back In The Spotlight

Revvity (RVTY) has put early type 1 diabetes detection in focus with the launch of its GSP T1D 3plex kit, a CE-IVDR-certified and fully automated multiplex autoantibody assay for population screening.

Recent trading has been strong, with Revvity’s share price delivering a 30-day return of 17.95% and a 90-day share price return of 35.99%. The 1-year total shareholder return of 67.84% points to building momentum around product updates and its upcoming Investor Day in November.

Scan beyond Revvity and find other diagnostics and life sciences players showing strong momentum with our curated 29 high quality undervalued stocks.

After a 68% 1-year total return and a share price above the average analyst target, investors in Revvity now face a tighter question. How much of the good news is already in the stock, and what does current valuation imply?

Most Popular Narrative: 18% Overvalued

Revvity last closed at $153.60, while the most followed narrative estimates fair value at about $130.27, using a discount rate of 8.5%. That gap puts the recent share price strength up against a view that much of the expected progress is already embedded in the stock.

The current valuation suggests that investors are already paying a premium for sustained growth in areas such as Signals software, reproductive health, and ex-China immunodiagnostics, even though the company’s longer-term revenue and EPS trends have been under pressure.

See why 10 investors see Revvity as 18% overvalued.

Result: Fair Value of $130.27 (OVERVALUED)

Still, if Revvity sustains operating margins in the upper 20s, or if Signals software growth reaccelerates faster than analysts model, that could challenge the 18% overvaluation view.

Find out about the key risks to this Revvity narrative.

Next Steps

Mixed sentiment around Revvity is clear, with both upside potential and concern in play. Move fast and stress test the story for yourself using our breakdown of 1 key reward and 2 important warning signs

Looking for more investment ideas beyond Revvity?

You have seen how quickly the Revvity story can shift. Do not leave your next move to chance when there are other opportunities worth lining up.

• Target stability first and scan a 31 resilient stocks with low risk scores that focuses on companies with more resilient profiles and controlled risk scores.
• Hunt for quality at a discount and review a 20 high quality undiscovered gems that highlights businesses with solid fundamentals flying under most investors’ radar.
• Prioritise financial strength and run through a list of solid balance sheet and fundamentals (25 results) for companies pairing durable balance sheets with grounded operating performance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com